Specific Diagnostics Revenue and Competitors

Location

$15.9M

Total Funding

Estimated Revenue & Valuation

  • Specific Diagnostics's estimated annual revenue is currently $6.3M per year.(i)
  • Specific Diagnostics's estimated revenue per employee is $125,500
  • Specific Diagnostics's total funding is $15.9M.

Employee Data

  • Specific Diagnostics has 50 Employees.(i)
  • Specific Diagnostics grew their employee count by -18% last year.

Specific Diagnostics's People

NameTitleEmail/Phone
1
VP Sales, US (Sold to bióMerieux in May, 2022 for $425M)Reveal Email/Phone
2
VP Sales, USReveal Email/Phone
3
R&D Operations DirectorReveal Email/Phone
4
Project ManagerReveal Email/Phone
5
Quality Assurance Engineer at Specific DiagnosticsReveal Email/Phone
6
Strategic Account DirectorReveal Email/Phone
7
Associate Principal Equipment EngineerReveal Email/Phone
8
Finance, Operations, and DevelopmentReveal Email/Phone
9
R&D MicrobiologistReveal Email/Phone
10
R&D MicrobiologistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is Specific Diagnostics?

Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specificᅢᄁ¬ツᆲ¬トᄁs Revealᅢᄁ¬ダᅡᄁ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specificᅢᄁ¬ツᆲ¬トᄁs unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specificᅢᄁ¬ツᆲ¬トᄁs system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing. Specific is located in Mountain View, California. For more information, visit www.specificdx.com. Corporate Contact, email: press@specificdx.com

keywords:Medical Devices, Diagnostics, Heathcare

$15.9M

Total Funding

50

Number of Employees

$6.3M

Revenue (est)

-18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Specific Diagnostics News

2022-04-20 - Potential diagnostic method for identifying human health-relevant nucleic acids utilizing FokI-assisted digestion of DNA duplexes and DNA/RNA hybrids

Developments in molecular diagnostics have been vital in discovering ... FokI is a unique restriction enzyme that identifies a certain DNA...

2022-04-17 - Specific Reveal Rapid AST Study with the Henry Ford Health ...

Specific Diagnostics has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid...

2022-04-17 - Clinical diagnosis of metabolic disorders using untargeted ...

Metabolite perturbations are evaluated based on current knowledge of specific metabolic pathway deficiencies, a manual diagnostic process that...

2021-06-29 - bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe

“Every lab we encounter wants rapid, easy-to-use susceptibility testing at the right price; we couldn’t reach them all without partnering with an organization with the scale and quality of bioMérieux,” said Paul A. Rhodes, Ph.D., CEO of Specific. SAN JOSE, Calif. (PRWEB) June 29, 2021 In the c ...

2020-06-02 - Specific Diagnostics Announces that NIAID has Awarded the Company a Further $2.9 million for the Commercial Development of the Reveal Rapid Antibiotic Susceptibility Testing (AST) System

MOUNTAIN VIEW, California, June 2, 2020 – Specific Diagnostics today announces that the National Institute for Allergy and Infectious Disease (NIAID) has awarded a second major grant to drive the commercial introduction of Specific’s Reveal system, which provides quantitative determination of an ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.8M5011%N/A
#2
$10.8M504%N/A
#3
$8.1M502%N/A
#4
$11M5043%N/A
#5
$10.5M50-9%$67.4M